Glycated haemoglobin and the risk of cardiovascular disease, diabetes and all-cause mortality in the Copenhagen City Heart Study

Journal of Internal Medicine

Volumn 273, Issue 1, 2013, Pages 94-101

  Eskesen, K ^a   Jensen, M T ^a   Galatius, S ^a   Vestergaard, H ^a,b   Hildebrandt, P ^c   Marott, J L ^d   Jensen, J S ^a,b,d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Cardiovascular risk factors; HbA1c; Risk factors

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DENMARK; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; URBAN POPULATION;

EID: 84871705453     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02594.x     Document Type: Article

References (31)

1. Goff DC Jr, Gerstein HC, Ginsberg HN et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99: 4i-20i.
2. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 1995; 18: 440-7.
3. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 1976; 295: 417-20.
4. Pettitt DJ, Knowler WC, Lisse JR, Bennett PH. Development of retinopathy and proteinuria in relation to plasma-glucose concentrations in Pima Indians. Lancet 1980; 2: 1050-2.
5. Engelgau MM, Thompson TJ, Herman WH et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997; 20: 785-91.
6. Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE. The national glycohemoglobin standardization program: a five-year progress report. Clin Chem 2001; 47: 1985-92.
7. World Health Organisation. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes. Abbreviated report of a WHO consultation. Geneva: World Health Organization, 2011.
8. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011; 34(Suppl 1): S62-9.
9. Selvin E, Steffes MW, Zhu H, Matsushita K et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362: 800-11.
10. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study. Diabetes Care 1996; 19: 450-6.
11. Lawlor DA, Fraser A, Ebrahim S, Smith GD. Independent associations of fasting insulin, glucose, and glycated haemoglobin with stroke and coronary heart disease in older women. PLoS Med 2007; 4: e263.
12. Jensen G, Schnohr P. The Copenhagen city heart study. Eur Heart J Suppl 2001; 3: 1-83.
13. Ollerton RL, Playle R, Ahmed K, Dunstan FD, Luzio SD, Owens DR. Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 1999; 22: 394-8.
14. Rohlfing C, Wiedmeyer HM, Little R et al. Biological variation of glycohemoglobin. Clin Chem 2002; 48: 1116-8.
15. Petersen PH, Jorgensen LG, Brandslund I, De Fine Olivarius N, Stahl M. Consequences of bias and imprecision in measurements of glucose and hba1c for the diagnosis and prognosis of diabetes mellitus. Scand J Clin Lab Invest Suppl 2005; 240: 51-60.
16. Khaw KT, Wareham N, Luben R et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322: 15-8.
17. de Vegt F, Dekker JM, Ruhe HG et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926-31.
18. Gerstein HC, Islam S, Anand S et al. Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15, 780 patients from the INTERHEART study. Diabetologia 2010; 53: 2509-17.
19. Ko GT, Chan JC, Tsang LW, Cockram CS. Combined use of fasting plasma glucose and HbA1c predicts the progression to diabetes in Chinese subjects. Diabetes Care 2000; 23: 1770-3.
20. Yoshinaga H, Kosaka K. High glycosylated hemoglobin levels increase the risk of progression to diabetes mellitus in subjects with glucose intolerance. Diabetes Res Clin Pract 1996; 31: 71-9.
21. Narayan KM, Hanson RL, Pettitt DJ, Bennett PH, Knowler WC. A two-step strategy for identification of high-risk subjects for a clinical trial of prevention of NIDDM. Diabetes Care 1996; 19: 972-8.
22. van't Riet E, Rijkelijkhuizen JM, Alssema M et al. HbA1c is an independent predictor of non-fatal cardiovascular disease in a Caucasian population without diabetes: a 10-year follow-up of the Hoorn Study. Eur J Prev Cardiol 2012; 19: 23-31.
23. Bonora E, Kiechl S, Mayr A et al. High-normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care 2011; 34: 1038-40.
24. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
25. Levin SR, Coburn JW, Abraira C et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000; 23: 1478-85.
26. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
27. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71.
28. Meigs JB, Nathan DM, Cupples LA, Wilson PW, Singer DE. Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. J Clin Epidemiol 1996; 49: 411-7.
29. Dagogo-Jack S. Pitfalls in the use of HbA(c) as a diagnostic test: the ethnic conundrum. Nat Rev Endocrinol 2010; 6: 589-93.
30. Herman WH, Ma Y, Uwaifo G et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007; 30: 2453-7.
31. Pani LN, Korenda L, Meigs JB et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care 2008; 31: 1991-6.